Ondansetron Dosing for a 14-Year-Old
For a 14-year-old patient, administer ondansetron 8 mg orally or IV, using the same adult dosing protocols based on the clinical indication 1.
Context-Specific Dosing
For Chemotherapy-Induced Nausea and Vomiting (CINV)
Moderately Emetogenic Chemotherapy:
- 8 mg orally twice daily (first dose 30 minutes before chemotherapy, second dose 8 hours later)
- Continue 8 mg every 12 hours for 1-2 days after chemotherapy completion 1
- The FDA label explicitly states that for pediatric patients 12 years and older, dosing is the same as adults 1
Highly Emetogenic Chemotherapy:
- 24 mg as three 8 mg tablets given 30 minutes before chemotherapy 1
- Note: The FDA label states there is no experience with 24 mg dosing in pediatric patients, so use clinical judgment 1
For Radiation-Induced Nausea and Vomiting
- 8 mg orally three times daily 2, 3
- Timing varies by radiation type:
- Total body irradiation: 1-2 hours before each fraction
- Single high-dose fraction to abdomen: 1-2 hours before, then every 8 hours for 1-2 days
- Daily fractionated radiotherapy: 1-2 hours before each fraction, then every 8 hours on treatment days 1
For Postoperative Nausea and Vomiting (PONV)
- 16 mg (two 8 mg tablets) given 1 hour before anesthesia induction 1
- FDA label notes no pediatric experience with this indication, but research supports 0.1-0.15 mg/kg IV (typically 8 mg for a 14-year-old) 4, 5
For Acute Gastroenteritis
- Single dose approach: 8 mg orally once in the emergency department
- Multi-dose approach: Recent high-quality evidence supports providing up to 6 doses of ondansetron (8 mg each) for home use over 48 hours, administered as needed for ongoing vomiting 6
- This reduced moderate-to-severe gastroenteritis from 12.5% to 5.1% (adjusted OR 0.50) 6
Key Clinical Considerations
Weight-Based vs. Fixed Dosing: At 14 years old, patients typically weigh enough that the standard adult 8 mg dose aligns with weight-based dosing (0.15 mg/kg IV or 0.1-0.15 mg/kg oral). The FDA label transitions to adult dosing at age 12 for chemotherapy indications 1.
Hepatic Impairment: If severe hepatic impairment exists (Child-Pugh ≥10), do not exceed 8 mg total daily dose 1.
QTc Prolongation: While ondansetron can prolong QTc interval, pediatric studies show this is rarely clinically significant. Research in children found no QTc prolongation even with divided dosing strategies 7.
Common Pitfall: Do not underdose adolescents by using pediatric 4 mg dosing. The FDA label clearly states that patients 12 years and older should receive adult 8 mg doses 1. Pediatric studies confirm that 12-18 year olds receiving 8 mg three times daily had similar efficacy to younger children receiving 4 mg three times daily 1.
Route Selection: Oral and IV routes have equivalent efficacy. Choose oral for convenience and cost-effectiveness when the patient can tolerate oral intake; use IV when vomiting is severe or oral route is compromised 1.